Although t-PA with or without heparin showed some improvement in VOD, its application is limited due to the occurrence of fatal bleeding.[20–22] The use of ATIII concentrate and PGE1 showed no beneficial effect on VOD.[23,24] A transjugular intrahepatic portosystemic stent-shunt may support the improvement of ascites; however, it has no benefit for jaundice and patient survival.[5,25] It may play a role as a bridging therapy to re-LT by improving VOD-induced severe portal hypertension. Here, PLAT is linked to portal hypertension.